Volume 16, Issue 13, Pages (October 2015)

Slides:

Advertisements

Similar presentations

Fever of unknown origin and cancer: a population-based study

Advertisements

Volume 370, Issue 9586, Pages (August 2007)

Volume 367, Issue 9517, Pages (April 2006)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 18, Issue 7, Pages (July 2017)

Volume 16, Issue 9, Pages (September 2015)

Volume 378, Issue 9809, Pages (December 2011)

Volume 372, Issue 9633, Pages (July 2008)

Building better therapy for children with acute lymphoblastic leukemia

Volume 9, Issue 8, Pages (August 2010)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 5, Issue 4, Pages (April 2006)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 9, Issue 5, Pages (May 2008)

Volume 13, Issue 3, Pages (March 2012)

Volume 14, Issue 3, Pages (March 2013)

Volume 372, Issue 9633, Pages (July 2008)

Volume 382, Issue 9886, Pages (July 2013)

Volume 16, Issue 8, Pages (August 2015)

Volume 15, Issue 8, Pages (July 2014)

Volume 14, Issue 10, Pages (September 2013)

Volume 9, Issue 9, Pages (September 2008)

Volume 15, Issue 4, Pages (April 2014)

Lessons taught by acute promyelocytic leukemia cure

Volume 373, Issue 9663, Pages (February 2009)

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 372, Issue 9642, Pages (September 2008)

Volume 2, Issue 6, Pages (June 2015)

Volume 9, Issue 10, Pages (October 2008)

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim.

Volume 18, Issue 7, Pages (July 2017)

Volume 389, Issue 10077, Pages (April 2017)

Volume 12, Issue 7, Pages (July 2011)

Volume 375, Issue 9732, Pages (June 2010)

Resuscitation at birth and cognition at 8 years of age: a cohort study

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Volume 387, Issue 10023, Pages (March 2016)

Volume 14, Issue 6, Pages (May 2013)

Volume 11, Issue 4, Pages (April 2010)

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 15, Issue 8, Pages (July 2014)

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 16, Issue 15, Pages (November 2015)

Volume 388, Issue 10055, Pages (October 2016)

Volume 15, Issue 6, Pages (May 2014)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile):

Volume 16, Issue 15, Pages (November 2015)

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Volume 5, Issue 4, Pages (April 2018)

Volume 378, Issue 9809, Pages (December 2011)

Volume 17, Issue 8, Pages (August 2016)

Low-technology approaches

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Volume 381, Issue 9871, Pages (March 2013)

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients by Alan K. Burnett,

Volume 376, Issue 9747, Pages (October 2010)

Volume 378, Issue 9802, Pages (October 2011)

Volume 372, Issue 9632, Pages (July 2008)

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Volume 14, Issue 7, Pages (June 2013)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Presentation transcript:

Volume 16, Issue 13, Pages 1295-1305 (October 2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial Prof Alan K Burnett, FMedSci, Prof Nigel H Russell, MD, Robert K Hills, DPhil, Prof David Bowen, MD, Jonathan Kell, MD, Steve Knapper, DM, Yvonne G Morgan, PhD, Jennie Lok, MSc, Angela Grech, BA, Gail Jones, MD, Prof Asim Khwaja, MD, Lone Friis, PhD, Prof Mary Frances McMullin, MD, Ann Hunter, MD, Prof Richard E Clark, MD, Prof David Grimwade, PhD The Lancet Oncology Volume 16, Issue 13, Pages 1295-1305 (October 2015) DOI: 10.1016/S1470-2045(15)00193-X Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile ATRA=all-trans retinoic acid. The Lancet Oncology 2015 16, 1295-1305DOI: (10.1016/S1470-2045(15)00193-X) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Quality-of-life outcomes (A) Global health status on the EORTC QLQ-C30 over time. Numbers at baseline are forms on which global health status was evaluable. (B) Results of all subscales of the EORTC QLQ-C30 and the HADS. Effect sizes were calculated so that in all cases a positive value represents a benefit for ATRA and arsenic trioxide treatment. ATRA=all-trans retinoic acid. EORTC=European Organisation for Research and Treatment of Cancer. HADS=Hospital Anxiety and Depression Scale. The Lancet Oncology 2015 16, 1295-1305DOI: (10.1016/S1470-2045(15)00193-X) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 Clinical outcomes (A) Cumulative incidence of haematological relapse. (B) Cumulative incidence of molecular or haematological relapse. (C) Overall survival in the intention-to-treat population. (D) Overall survival in low-risk patients (white blood cell count 0–9·9 × 109 cells per L). (E) Overall survival in high-risk patients (white blood cell count ≥10 × 109 cells per L). (F) Overall survival in patients older than 60 years of age. ATRA=all-trans retinoic acid. *Two patients in the ATRA and idarubicin group (one high risk and one low risk) had no follow-up data available for survival or relapse. The Lancet Oncology 2015 16, 1295-1305DOI: (10.1016/S1470-2045(15)00193-X) Copyright © 2015 Elsevier Ltd Terms and Conditions